Axsome Therapeutics

NASDAQ:AXSM

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.

Investing News NetworkYour trusted source for investing success

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

13 Canadian Crypto ETFs (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

Rare Earths Stocks: 9 Biggest Companies in 2024

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Investing in Graphene Companies (Updated 2024)

When is the Starlink IPO Date and Can You Invest? (Updated 2024)

US$30 Million Prepayment Term Sheet and Offtake Agreement Executed with a Global Commodities Trader

Radiopharm achieves Nasdaq listing of ADS

SAGA Metals Reports Channel Sample Assay Results at Double Mer Uranium Project

SAGA Metals Completes OTCQB Listing and Receives DTC Eligibility

Mount Hope Mining: Advancing a Copper, Gold-rich Asset in the Cobar Basin of New South Wales

Significant Milestone Achieved in Development Journey with The Completion of The "first phase" of the Environmental Impact Assessment Procedure for Rajapalot Gold-Cobalt Project

Purpose Bitcoin ETF

Soma Gold Corp.

First Helium

GTI Energy

2024 Gold Outlook Report

2024 Uranium Outlook

Silver Price Forecast - What Happened And Where Do We Go From Here?

Rare Earths Outlook Report

Axsome Therapeutics

Axsome Therapeutics Announces Results of MINDSET Physician Survey

Axsome Therapeutics Provides Year End 2018 Clinical Update

Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder

Interactive Chart